Lieuwe J Melchers1, Martijn J A M Clausen2, Mirjam F Mastik3, Lorian Slagter-Menkema4, Johannes A Langendijk5, Bernard F A M van der Laan6, Jacqueline E van der Wal3, Bert van der Vegt3, Jan L N Roodenburg7, Ed Schuuring3. 1. Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address: l.j.melchers@umcg.nl. 2. Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 3. Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 4. Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Otorhinolaryngology/Head and Neck Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 5. Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 6. Department of Otorhinolaryngology/Head and Neck Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 7. Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Abstract
PURPOSE: To assess the prevalence of EGFRvIII, a specific variant of EGFR (epidermal growth factor receptor), in 3 well-defined cohorts of head and neck squamous cell carcinoma (HNSCC). METHODS AND MATERIALS: Immunohistochemistry for the specific detection of EGFRvIII using the L8A4 antibody was optimized on formalin-fixed, paraffin-embedded tissue using glioblastoma tissue. It was compared with EGFR and EGFRvIII RNA expression using a specific reverse transcription-polymerase chain reaction also optimized for formalin-fixed, paraffin-embedded tissue. Tissue microarrays including 531 HNSCCs of various stages with complete clinicopathologic and follow-up data were tested for the presence of EGFRvIII. RESULTS: None of the 531 cases showed EGFRvIII protein expression. Using an immunohistochemistry protocol reported by others revealed cytoplasmic staining in 8% of cases. Reverse transcription-polymerase chain reaction for the EGFRvIII transcript of the 28 highest cytoplasmic staining cases, as well as 69 negative cases, did not show expression in any of the tested cases, suggesting aspecific staining by a nonoptimal protocol. CONCLUSIONS: The EGFRvIII mutation is not present in HNSCC. Therefore, EGFRvIII does not influence treatment response in HNSCC and is not a usable clinical prognostic marker.
PURPOSE: To assess the prevalence of EGFRvIII, a specific variant of EGFR (epidermal growth factor receptor), in 3 well-defined cohorts of head and neck squamous cell carcinoma (HNSCC). METHODS AND MATERIALS: Immunohistochemistry for the specific detection of EGFRvIII using the L8A4 antibody was optimized on formalin-fixed, paraffin-embedded tissue using glioblastoma tissue. It was compared with EGFR and EGFRvIII RNA expression using a specific reverse transcription-polymerase chain reaction also optimized for formalin-fixed, paraffin-embedded tissue. Tissue microarrays including 531 HNSCCs of various stages with complete clinicopathologic and follow-up data were tested for the presence of EGFRvIII. RESULTS: None of the 531 cases showed EGFRvIII protein expression. Using an immunohistochemistry protocol reported by others revealed cytoplasmic staining in 8% of cases. Reverse transcription-polymerase chain reaction for the EGFRvIII transcript of the 28 highest cytoplasmic staining cases, as well as 69 negative cases, did not show expression in any of the tested cases, suggesting aspecific staining by a nonoptimal protocol. CONCLUSIONS: The EGFRvIII mutation is not present in HNSCC. Therefore, EGFRvIII does not influence treatment response in HNSCC and is not a usable clinical prognostic marker.
Authors: Mihály Cserepes; Györgyi A Nelhűbel; Mónika Meilinger-Dobra; Adrienn Herczeg; Dóra Türk; Zita Hegedűs; Laura Svajda; Erzsébet Rásó; Andrea Ladányi; Kristóf György Csikó; István Kenessey; Árpád Szöőr; György Vereb; Éva Remenár; József Tóvári Journal: Cancers (Basel) Date: 2022-05-13 Impact factor: 6.575
Authors: Koos Koole; Martijn J A M Clausen; Robert J J van Es; Pauline M W van Kempen; Lieuwe J Melchers; Ron Koole; Johannes A Langendijk; Paul J van Diest; Jan L N Roodenburg; Ed Schuuring; Stefan M Willems Journal: Mol Diagn Ther Date: 2016-08 Impact factor: 4.074
Authors: Dominik Thomas Koch; Anja Pickhard; Lena Gebel; Anna Maria S Buchberger; Murat Bas; Carolin Mogler; Rudolf Reiter; Guido Piontek; Markus Wirth Journal: Oncotarget Date: 2017-05-16